pemoline has been researched along with MS (Multiple Sclerosis) in 15 studies
Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.
pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue." | 9.08 | Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995) |
| "Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS." | 9.08 | The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996) |
| "Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients." | 6.67 | A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. ( Bass, B; Ebers, GC; Penman, M; Rice, GP; Weinshenker, BG, 1992) |
| "To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue." | 5.08 | Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995) |
| "Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS." | 5.08 | The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996) |
| " Search terms included multiple sclerosis, fatigue, medication treatments, amantadine, modafinil, aspirin, acetyl-l-carnitine, pemoline, 4-aminopyridine and randomized controlled trial (RCT)." | 4.95 | Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. ( Deng, XY; Wang, L; Yang, TT; Yu, G, 2017) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| " Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis." | 4.86 | Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010) |
| " Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term." | 4.80 | Treatments for fatigue in multiple sclerosis: a rapid and systematic review. ( Brañas, P; Burls, A; Fry-Smith, A; Hyde, C; Jordan, R, 2000) |
| "We present a case of pemoline-induced autoimmune hepatitis in a 46-yr-old woman who received the drug for management of her multiple sclerosis." | 3.69 | Pemoline-induced autoimmune hepatitis. ( Grace, ND; Kane, M; Sterling, MJ, 1996) |
| "Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients." | 2.67 | A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. ( Bass, B; Ebers, GC; Penman, M; Rice, GP; Weinshenker, BG, 1992) |
| "Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
| "Fatigue is recognized as one of the most disabling and common symptoms of MS." | 2.44 | Treating fatigue. ( Hum, S; Lapierre, Y, 2007) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "Fatigue is a common symptom in patients with multiple sclerosis." | 2.40 | ['Fatigue' in multiple sclerosis]. ( Hohlfeld, R; Zimmermann, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, TT | 1 |
| Wang, L | 1 |
| Deng, XY | 1 |
| Yu, G | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 2 |
| Peuckmann, V | 1 |
| Elsner, F | 1 |
| Krumm, N | 1 |
| Trottenberg, P | 1 |
| Induruwa, I | 1 |
| Constantinescu, CS | 1 |
| Gran, B | 1 |
| Schwid, SR | 1 |
| Murray, TJ | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Lapierre, Y | 1 |
| Hum, S | 1 |
| Krupp, LB | 3 |
| Coyle, PK | 2 |
| Doscher, C | 2 |
| Miller, A | 1 |
| Cross, AH | 1 |
| Jandorf, L | 1 |
| Halper, J | 1 |
| Johnson, B | 1 |
| Morgante, L | 1 |
| Grimson, R | 1 |
| Geisler, MW | 1 |
| Sliwinski, M | 1 |
| Masur, DM | 1 |
| Sterling, MJ | 1 |
| Kane, M | 1 |
| Grace, ND | 1 |
| Dulli, D | 1 |
| Schutta, H | 1 |
| Zimmermann, C | 1 |
| Hohlfeld, R | 1 |
| Brañas, P | 1 |
| Jordan, R | 1 |
| Fry-Smith, A | 1 |
| Burls, A | 1 |
| Hyde, C | 1 |
| Christodoulou, C | 1 |
| Weinshenker, BG | 1 |
| Penman, M | 1 |
| Bass, B | 1 |
| Ebers, GC | 1 |
| Rice, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900] | 0 participants (Actual) | Interventional | 2012-02-29 | Withdrawn (stopped due to Was unable to recruit subjects) | |||
| Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820] | 105 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for pemoline and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
Topics: 4-Aminopyridine; Amantadine; Central Nervous System Stimulants; Dopamine Agents; Drug Therapy; Fatig | 2017 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney | 2010 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
Treating fatigue.
Topics: Amantadine; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Dopamine Agents | 2007 |
['Fatigue' in multiple sclerosis].
Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis; | 1999 |
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Topics: Amantadine; Central Nervous System Stimulants; Cost-Benefit Analysis; Dopamine Agents; Evidence-Base | 2000 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
3 trials available for pemoline and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Attention; Central Nervous System Stimulants; C | 1996 |
A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis.
Topics: Adult; Double-Blind Method; Fatigue; Humans; Middle Aged; Multiple Sclerosis; Pemoline | 1992 |
3 other studies available for pemoline and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Treating fatigue in patients with MS: one step forward, one step back.
Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants | 2005 |
Pemoline-induced autoimmune hepatitis.
Topics: Antibodies, Antinuclear; Autoantibodies; Autoimmune Diseases; Central Nervous System Stimulants; Che | 1996 |
Fatigue in MS.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Pemoline | 1996 |